Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001140361-23-051002
Filing Date
2023-11-02
Accepted
2023-11-02 07:30:36
Documents
4

Document Format Files

Seq Description Document Type Size
1 DEFM14A edge20012673x2_defm14a.htm DEFM14A 2758663
2 edge20012673x2_pc-01x1.jpg GRAPHIC 618802
3 edge20012673x2_pc-02x1.jpg GRAPHIC 453861
4 logo_mirati.jpg GRAPHIC 57470
  Complete submission text file 0001140361-23-051002.txt   4315221
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-35921 | Film No.: 231370087
SIC: 2834 Pharmaceutical Preparations